Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
145M
-
Number of holders
-
190
-
Total 13F shares, excl. options
-
106M
-
Shares change
-
+12.9M
-
Total reported value, excl. options
-
$2.94B
-
Value change
-
+$355M
-
Put/Call ratio
-
0.17
-
Number of buys
-
106
-
Number of sells
-
-73
-
Price
-
$27.81
Significant Holders of Denali Therapeutics Inc. - Common Stock (DNLI) as of Q4 2022
221 filings reported holding DNLI - Denali Therapeutics Inc. - Common Stock as of Q4 2022.
Denali Therapeutics Inc. - Common Stock (DNLI) has 190 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 106M shares
of 145M outstanding shares and own 72.81% of the company stock.
Largest 10 shareholders include BAILLIE GIFFORD & CO (15.1M shares), VANGUARD GROUP INC (9.95M shares), BlackRock Inc. (9.32M shares), Crestline Management, LP (6.86M shares), Temasek Holdings (Private) Ltd (6.52M shares), WELLINGTON MANAGEMENT GROUP LLP (5.12M shares), STATE STREET CORP (4.85M shares), ARCH Venture Management, LLC (3.67M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.65M shares), and Flagship Pioneering Inc. (2.62M shares).
This table shows the top 190 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.